Physician profile
Ramit Kahlon
NPI 1841267614
$5,967.47
in general payments reported to CMS, 2019-2025
49 companies · $855 in 2025
The $855 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $596 · 2021: $1,540 · 2022: $728 · 2023: $981 · 2024: $706 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $738.70 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $676.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $395.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $348.92 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $320.59 | 2019-2022 | |
| Abbott Laboratories | $262.79 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Jot Dx |
| Lilly USA, LLC | $206.70 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Amarin Pharma, INC. | $183.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.49 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $182.58 | 2020-2024 | Lux-Dx Insertable Cardiac Monitor |
| Novartis Pharmaceuticals Corporation | $176.55 | 2019-2023 | |
| Lundbeck LLC | $174.48 | 2023-2025 | Rexulti |
| Pfizer INC. | $148.46 | 2019-2025 | |
| Amgen INC. | $132.61 | 2021-2024 | Repatha, Otezla, Prolia |
| Daiichi Sankyo INC. | $120.09 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramit Kahlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.